Cargando…
A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting: R-EFECT study
BACKGROUND: Several clinical trials in chronic phase (CP) chronic myeloid leukemia (CML) showed that early response to tyrosine kinase inhibitor (TKI) treatment results in an improved long-term survival and progression-free survival. This study assessed whether patients achieving early treatment res...
Autores principales: | Petzer, Andreas L., Sperr, Wolfgang R., Buxhofer-Ausch, Veronika, Sliwa, Thamer, Schmidt, Stefan, Greil, Richard, Wölfler, Albert, Pichler, Petra, Dormann, Clemens, Burgstaller, Sonja, Tinchon, Christoph, Lang, Alois, Goebel, Florian, Uthman, Shanow, Muenchmeier, Niklas, Valent, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445202/ https://www.ncbi.nlm.nih.gov/pubmed/32533444 http://dx.doi.org/10.1007/s00508-020-01690-1 |
Ejemplares similares
-
Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
por: Krauth, Maria-Theresa, et al.
Publicado: (2018) -
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014) -
"Conversation club efectiveness to improve students´speaking skill" : /
por: Paz Cruz, Nínive del Carmen
Publicado: (2014) -
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019) -
Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)